Wolfe Research reiterates Oracle stock rating on strong demand

Oracle reported Q3 FY2026 EPS of $1.79 vs $1.70 expected (5.29% beat) and revenue of $17.2B vs $16.92B consensus. Management raised FY2027 revenue guidance to $90B from $89B and reiterated FY2026 capex guidance of ~$50B despite a $19B quarter of capex (≈$5B above estimates); remaining performance obligations rose $29B q/q. The company added 400MW of capacity in Q3 (800MW TTM) with AI gross margins of 32%, and analysts boosted price targets (Barclays $230→$240; Wolfe reiterated Outperform with $215 PT), while the stock trades at $149.40 (market cap $429B) and is down ~51% over six months, leaving valuation metrics (PEG ~0.93) looking relatively attractive.

Analysis

Oracle’s clearer AI infrastructure story reduces an ambiguity tax but does not automatically convert to durable software-like multiples — the re-rating requires sustained improvement in incremental gross margins and visibility that backlog converts into higher-margin recurring revenue over multiple quarters. Expect the market to reward sequential proofs of margin accretion (2–4 quarters) rather than one-off beats; the stock is likely to move in step with quarterly cadence of capacity activation and contract start-dates rather than headline guidance revisions.

Second-order winners are the OEM and accelerator supply chain: GPU and chassis suppliers will see lumpy, front-loaded demand that tightens component lead times and benefits suppliers’ pricing power near-term, while BYOH-friendly customers shift spend away from vendor-captured hardware margin into services and software. Hyperscalers have two levers to blunt Oracle’s momentum — price competition and custom silicon — which could force margin compression across the AI infra market if hyperscalers accelerate subsidies to defend enterprise workloads.

Tail risks: a GPU supply shock, a macro-led enterprise AI spending pullback, or higher-than-expected equity dilution via ATM taps would rapidly reverse sentiment; these play out on different cadences (supply shock = weeks, spending pause = 1–4 quarters, dilution = immediate upon issuance). Monitor OEM build schedules, three-month utilization ramp indicators, and OEM channel inventory metrics as near-real-time leading indicators for revenue conversion and margin sustainability.

Catalysts to watch: multi-quarter sequential gross-profit expansion for AI capacity, quarter-over-quarter reduction in time-to-revenue from backlog, and public hyperscaler price responses. Absent these, the market may treat the narrative as partially priced, making volatility around macro prints (rates/CPI) and supply updates the primary tradeable drivers over the next 3–6 months.

Key Decisions for Investors

• Long ORCL via a 12–18 month call-spread (buy Jan-2027 160 calls / sell Jan-2027 240 calls) sized to 2–3% portfolio risk: asymmetric upside if Oracle proves sustained AI gross-margin expansion; max loss = premium (~2–3% PF), potential upside = ~3–4x if re-rating occurs.
• Pair trade: Long ORCL equity (3–6 month horizon) funded with a small short position in AMZN (cloud exposure) or MSFT to hedge macro-driven multiple compression — target a 60/40 sizing (60% long ORCL equity / 40% short AMZN/MSFT) to capture idiosyncratic re-rating while limiting beta risk.
• Long NVDA 3–6 month calls (buy-to-open) as a play on GPU demand ramp from enterprise infra rollouts; cap exposure to 1–2% portfolio risk. This is a supply-chain hedge that profits if increased infra deployments tighten component markets and lift GPU pricing.
• Short stealth risk: buy a 9–12 month put spread on a large hyperscaler (e.g., AMZN or MSFT) to protect against aggressive price competition or margin compression in cloud services (buy 1 deep OTM put / sell lower strike for cost control). Size as a hedge equal to ~25–35% of ORCL long notional.
• Event monitor: if Oracle signals meaningful ATM facility usage or announces stretched capital allocation (equity issuance / large M&A), reduce long exposure by 50% immediately and rotate proceeds into short-dated volatility trades on ORCL (buy 0–60 day puts) to capture downside that follows dilution news.